Skye Bioscience
CompanyUnited States
Skye Bioscience develops one asset, in phase 2 (nimacimab in obesity). Mostly antibody acting on lipid and ceramide metabolism and CNR1; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 2
- 1
- Trial
- 1
- Signal
Pipeline
1Peripherally restricted antibody acts as a CB1 receptor inverse agonist to promote weight loss.
Phase 2, Antibody, Lipid and ceramide metabolism, CNR1, obesity, overweight
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials1
- Signals2
- Similar companies6
Papers
ADA Scientific Sessions 2026 abstract, 6 Jun 2026